Revathi Equip (RVTH)
CyclicalScore breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹729.9 |
| Market Cap | ₹223.86 Cr |
| P/E Ratio | 16.18 |
| ROCE | 25.71% |
| ROE | 7.35% |
| Dividend Yield | 0% |
| Profit Growth | 255.1% |
| Debt/Equity | 0.48 |
| Sales Growth | 34.9% |
| Promoter Holding | 63.89% |
| 52-Week Range | ₹491.1 — ₹1,300 |
| Sector | Industrial Manufacturing |
| Book Value | ₹458.11 |
Strengths
- ROCE of 25.71% reflects strong operational capital efficiency even during a downturn.
- Debt-to-equity of 0.42 provides a reasonable balance-sheet cushion during the current loss-making phase.
- Promoter holding of 63.89% aligns management interests with minority shareholders.
- Book value of ₹372.89 and P/B of 1.65 offer some reference support, though not deep value.
Concerns
- Sales growth of -23.81% and profit growth of -800% with a latest-quarter net loss of ₹1 Cr indicate severe earnings erosion.
- Piotroski F-Score of 3/9 points to deteriorating fundamentals and weakened financial health.
- ROE of only 7.35% shows poor returns to shareholders relative to the company's headline ROCE.
- P/E of 21.09 on collapsing profits is not cheap, and the stock pays no dividend, leaving no income cushion.
AI Analysis
When I look at Revathi Equip, I start with the business, not the ticker. This is an industrial products company, and the numbers tell me we are in the middle of a rough patch. Sales have contracted by 23.81%, profit growth has swung to -800%, and the latest quarter shows a net loss of ₹1 Cr on sales of ₹32 Cr. The Piotroski F-Score of 3/9 confirms deterioration across profitability, leverage and efficiency. A business that cannot grow sales and is now losing money does not fit my definition of a great compounder. Still, there are some signs of decent capital allocation: ROCE stands at 25.71%, which suggests the underlying operations can generate returns when conditions are normal. Debt-to-equity of 0.42 is manageable, and promoter holding of 63.89% keeps ownership aligned. But from a Graham perspective, valuation matters. At ₹616.15, the market cap is ₹188 Cr, 1.65 times book value and 21.09 times earnings. That is not a distressed price; it is a price that assumes the bad period is temporary. With no dividend yield, the investor is relying entirely on future profit recovery. The 52-week range of ₹491.10 to ₹1300.00 shows how quickly sentiment has reversed. I would not be a buyer today without clear evidence that sales have stabilised and profit has turned positive. I need a margin of safety, and a falling knife with an F-Score of 3 does not offer one. I would keep it on my watchlist, not in my portfolio. Watch the next few quarters for order flows, margin recovery, debt servicing, and any signs that the ROCE advantage is being rebuilt. Until then, patience is the better strategy.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer